Related Experiment Video

Updated: Jul 17, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Does the C-type natriuretic peptide have prognostic value in chagas disease and other dilated cardiomyopathies?

Silvia Heringer-Walther1, Maria da Consolação V Moreira, Niels Wessel

  • 1Department of Cardiology and Pneumology, CUM, Campus Benjamin Franklin (CBF), Berlin, Germany.

Journal of Cardiovascular Pharmacology
|January 6, 2007
PubMed

Insights

C-type natriuretic peptide (CNP) levels are elevated in advanced Chagas disease (CD) and dilated cardiomyopathy (DCM) but do not predict outcomes, unlike ANP and BNP. This study highlights CNP

Area of Science:

  • Cardiology
  • Biomarkers
  • Tropical Diseases

Background:

  • Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are established heart failure (HF) biomarkers.
  • Chagas disease (CD), caused by Trypanosoma cruzi, is a significant cause of HF in Latin America.
  • Dilated cardiomyopathies (DCM) encompass various heart muscle diseases leading to HF.

Purpose of the Study:

  • To investigate the diagnostic and prognostic value of C-type natriuretic peptide (CNP) in patients with Chagas disease (CD) and other causes of dilated cardiomyopathy (DCM).
  • To compare the predictive power of CNP with established natriuretic peptides (ANP, BNP) in these patient populations.

Main Methods:

  • Radioimmunoassay was used to measure plasma CNP concentrations in 66 CD patients, 50 DCM patients, and 30 healthy controls.
  • Patients were classified by New York Heart Association (NYHA) functional class.
  • Follow-up data on mortality and heart transplantation were collected over a median of 31.4 months.

Main Results:

  • CNP concentrations were significantly elevated only in patients with severe (NYHA class III-IV) CD and DCM.
  • CNP showed a correlation with left-ventricular end-systolic volume in DCM patients but not in CD patients.
  • CNP levels did not predict mortality or the need for heart transplantation in either group.

Conclusions:

  • This study provides the first evidence of elevated CNP levels in Chagas disease and other dilated cardiomyopathies.
  • Unlike ANP and BNP, CNP lacks significant diagnostic or prognostic value for heart failure outcomes in CD and DCM.
  • Further research may explore the specific role of CNP in the pathophysiology of these cardiomyopathies.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...